日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adherence to 6-Mercaptopurine (6-MP) and Habit Strength in Pediatric Acute Lymphoblastic Leukemia (ALL)

儿童急性淋巴细胞白血病 (ALL) 患者对 6-巯基嘌呤 (6-MP) 的依从性及习惯强度

Yang, Mira Muxi; Singh, Revika; Haugen, Maureen; Duff, Ashley; Shoop, Jenny; Morgan, Elaine R; Rossoff, Jenna E; Weinstein, Joanna L; Heneghan, Mallorie B; Badawy, Sherif M

Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

ORIC-101(一种糖皮质激素受体拮抗剂)与恩杂鲁胺联合治疗恩杂鲁胺治疗期间病情进展的转移性去势抵抗性前列腺癌患者的 I 期研究

Wassim Abida, Andrew W Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Rongda Xu, Jian Wang, Shravani Barkund, Aleksandr Pankov, Amber Wang, Melissa R Junttila, Pratik S Multani, Anneleen Daemen, Edna Chow

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

ORIC-101(一种糖皮质激素受体拮抗剂)与白蛋白结合型紫杉醇联合用于治疗晚期实体瘤患者

Christopher T Chen, Vishesh Khanna, Shivaani Kummar, Raghad M Abdul-Karim, David Sommerhalder, Anthony W Tolcher, Naoto T Ueno, Sarah Lindsey Davis, Douglas W Orr, Erika Hamilton, Manish R Patel, Alexander I Spira, Shekeab Jauhari, Vaia Florou, Maureen Duff, Rongda Xu, Jian Wang, Shravani R Barkund,